Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of $428 million specializing in mRNA therapeutics and vaccines, stands at a ...

WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA – a genetically validated target that provides a new approach for healthy, ...

Discover how mRNA-based blood clots offer a promising new treatment for osteoarthritis, potentially surpassing traditional ...

Following the lead of previous work on mRNA-based vaccines, therapies for spinal cord injuries and more, the method relies upon mineral-coated microparticles to deliver mRNA that encodes for ...

Moderna (MRNA) closed the latest trading day at $41.66, indicating a +0.6% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily loss of 1.46%. Elsewhere ...

The mRNA-1273.815 vaccine provided significant protection against COVID-19-related hospitalizations and medically attended COVID-19 among US adults.

Russia cancer vaccine could receive approval by August allowing treatment to begin the head of the Gamaleya Research ...

Meet the woman leading vaccine innovation in Senegal to fight Rift Valley fever and empower Africa’s next generation of ...

Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...